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Abstract
cdx4, a caudal-related homeodomain-containing transcription factor, functions as a regulator of hox genes,
thereby playing a critical role in anterior–posterior (A-P) patterning during embryogenesis. In zebraﬁsh,
homozygous deletion of the cdx4 gene results in a mutant phenotype known as kugelig, with aberrant A-P
patterning and severe anemia characterized by decreased gata1 expression in the posterior lateral mesoderm. To
identify pathways that interact with cdx4 during primitive hematopoiesis, we conducted a chemical genetic
screen in the cdx4 mutant background for compounds that increase gata1 expression in cdx4 mutants. Among
2640 compounds that were tested, we discovered two compounds that rescued gata1 expression in the cdx4-
mutant embryos. The strongest rescue was observed with bergapten, a psoralen compound found in bergamont
oil. Another member of the psoralen family, 8-methoxypsoralen, was also found to rescue gata1 expression in
cdx4-mutant embryos. The psoralen compounds also disrupted normal A-P patterning of embryos. These
compounds modify the cdx4-mutant phenotype and will help elucidate signaling pathways that act downstream
or parallel to the cdx4-hox pathway.
Introduction
B
ecause of their small size, optical clarity, and sub-
stantial fecundity, zebraﬁsh embryos are excellent tools
for testing the effects of chemicals in vivo in a vertebrate ani-
mal model. Several recent studies have proven the efﬁcacy of
chemical screening using zebraﬁsh embryos, identifying
small molecules regulating hematopoietic stem cell emer-
gence as well as other developmental pathways.
1–11 Because
most developmental and signaling pathways are conserved
between mammals and teleosts, chemicals discovered using
this approach in zebraﬁsh are likely to be applicable to
humans. In addition, characterizing the mechanism of action
of compounds discovered in this type of screen may lead to
new insights into the function of a speciﬁc gene of interest.
To date, most of the published chemical screens using
zebraﬁsh have been performed using wild-type embryos.
Anotheradvantageofthezebraﬁshmodelistheavailabilityof
many mutant strains and transgenic strains with phenotypes
analogous to human diseases, which can be utilized in che-
mical screens.
12 Two such chemical modiﬁer screens have
been published to date. The ﬁrst took advantage of a vascular
mutant called gridlock, with a mutation in the hey2 gene.
1 The
second utilized the crash-and-burn mutant, with a defect in cell
cycle regulation.
2 Performing a chemical screen on a mutant
background allows selection of compounds that rescue the
phenotype of interest, with the hope of identifying modifying
signaling pathways and potentially ﬁnding therapeutically
relevant molecules.
The zebraﬁsh has also proven to be an excellent model to
study blood development, and forward genetic screens have
generated numerous blood mutants that have advanced the
understanding of developmental hematopoiesis.
13,14 As in
mammals, hematopoiesis in the zebraﬁsh consists of two
waves. The primitive or embryonic wave occurs during the
ﬁrst 24h postfertilization, specifying blood cell development
in the anterior lateral mesoderm (ALM) and posterior lateral
mesoderm (PLM). Blood cells born in the ALM region become
myeloid cells, expressing the myeloid transcription factor
pu.1, whereas the PLM region gives rise to some myeloid cells
but mostly erythroid cells, a process that is governed by the
transcription factor gata1.
15–17 Deﬁnitive hematopoiesis starts
later and generates hematopoietic stem cells, which will
produce all blood cell types for the animal’s lifetime.
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61The zebraﬁsh mutant kugelig, with a deletion in the caudal-
related homeobox gene cdx4, has aberrant anterior–posterior
(A-P) patterning and hox gene expression, in addition to se-
vere anemia due to failed speciﬁcation of PLM cells into
gata1þ erythroid cells.
18 At the 10-somite stage, cdx4 mutants
show decreased expression of gata1 in the PLM. This defect
in primitive hematopoiesis can be partially rescued by 4-
diethylamino benzaldehyde (DEAB), an inhibitor of retinoic
acid (RA) biosynthesis
19 (J.L.O. de Jong and L.I. Zon, un-
published data).
In this study, we conducted a chemical screen using
cdx4-mutant embryosto seek new pathways that interact with
cdx4 during primitive hematopoiesis. A total of 2640 com-
pounds were tested, revealing two that rescued gata1 expres-
sion in cdx4-mutant embryos. Bergapten, also known as
5-methoxypsoralen(5-MOP),producedthemostrobustrescue
of all the compounds tested. Bergapten was found to have
effects similar to DEAB, including changes in A-P pattern-
ing. Neither bergapten nor DEAB signiﬁcantly alters the
expression of other blood genes including ﬂi1, scl, and pu.1 in
wild-type embryos. However, similar to the rescue of gata1
expression, bergapten and DEAB both rescue the expres-
sion of pu.1 in cdx4-mutant embryos. The related compound
8-methoxypsoralen (8-MOP) was also shown to affect A-P
patterning and to rescue loss of gata1 and pu.1 in cdx4-mutant
embryos. This indicates that psoralen compounds may inter-
act with cdx4-hox downstream pathway or a parallel pathway.
Methods
Zebraﬁsh care and mutant lines
Wild-type AB strain, and kugelig heterozygote zebraﬁsh
carrying the cdx4-mutant allele were bred and maintained
using standard zebraﬁsh husbandry.
20 Developmental stag-
ing was done by embryo morphology.
21 All zebraﬁsh exper-
iments and procedures were performed as approved by the
Children’sHospitalBostonInstitutionalAnimalCareandUse
Committee.
Chemical library
Compounds from the known bioactives collection (NINDS
Custom Collection 2, Biomol 3, Prestwick 1, and Biomol 4)
were obtained from the Institute of Chemistry and Cell Biol-
ogy (ICCB) Longwood screening facility at Harvard Medical
School. A total of 2640 compounds were screened. The ICCB
compounds were stored at  208C, dissolved in 100% di-
methyl sulfoxide (DMSO) in desiccated storage containers in
384-well plates. All chemical transfers were performed ro-
botically. One microliter ofeach compound dissolved in 100%
DMSO was diluted into 300mL of embryo medium (E3 ﬁsh-
water)
20with1%penicillin=streptomycin(Invitrogen) and1%
DMSO in a 48-well nontissue culture-treated plate (Falcon).
In addition, each 48-well plate contained blank wells used
as negative control wells (E3 water with 1% DMSO and
1% Pen=Strep) and positive control wells with 20mM DEAB.
Chemicals
Stock solutions were prepared as follows: DEAB
(Sigma-Aldrich) was dissolved at 1M concentration in DMSO
(Sigma-Aldrich). Bergapten (Sigma-Aldrich) was dissolved
in acetone at 5mM concentration. 8-MOP (Sigma-Aldrich)
was dissolved in acetone at 5mM concentration. 5-(4-
Phenoxybutoxy)psoralen (PAP-1) (Sigma-Aldrich) was dis-
solved inDMSO at 7.25mMconcentration. All stocksolutions
were stored at  208C, and fresh dilutions of working con-
centrations were prepared on the day of experiments.
Screening procedure
cdx4 heterozygous ﬁsh were mated every 1–2 weeks to
generate embryos for screening. Males and females were set
up overnight and kept separated until morning when they
were allowed to mate and the embryos were collected. Em-
bryos werekept at288Cuntil treatmentwith chemicals.When
embryos reached the dome stage, dead and unfertilized em-
bryos were discarded, and healthy stage-synchronized em-
bryos were pooled. At the 50% epiboly stage, approximately
20 embryos per well were arrayed in the 48-well plates con-
taining one compound per well. As cdx4 affects early meso-
dermal patterning, embryos were treated from the beginning
ofgastrulation(50%epibolystage) untilthe10-somite stageto
ﬁnd compounds that could overcome the need for cdx4 in
specifying primitive blood cells. Following the incubation at
218Cfor approximately 14–15h, embryosweredechorionated
by incubation in pronase 167mg=mL (Roche) for 6min. They
were then washed repeatedly with E3 water to remove the
chorions and the treatment chemicals and then ﬁxed in 4%
paraformaldehyde for whole-mount in situ hybridization
with gata1 and cdx4 riboprobes (Fig. 1). The bilateral mRNA
expression of gata1, a transcription factor critical for erythroid
development, was used as the readout for the screen, with
positive hits showing increased gata1 in cdx4-mutant em-
bryos. cdx4-mutant embryos were easily identiﬁed in each
wellbythelackofcdx4RNAexpressioninthemidlineandthe
tail bud (Fig. 1).
After in situ hybridization, embryos were transferred into
24-well plates to minimize optical distortion from the smaller
wells in the 48-well plates. Each well was scored manually
using a dissecting microscope. To minimize the inﬂuence of
plate-to-plate variation of the scoring results, two negative
control wells (E3þ1% DMSO and 1% Pen=Strep) and two
positivecontrolwells(20mMDEAB)wereincludedineach24-
well plate. For each well, the number of mutant embryos was
recorded, along with the level of gata1 expression relative to
the positive and negative controls for that plate. If the ex-
pression was deemed to be increased in comparison to the
negative control wells, the level of increase was scored based
on the intensity of gata1 staining in the mutant embryos and
the percentage of total mutants with increased gata1. We as-
signed each compound to a distinct level of rescue (Fig. 2).
Level 3 compounds had the strongest gata1 expression with
>50% of mutant embryos uniformly displaying as much or
more gata1 expression as the positive controls from the same
plate. Level 2 compounds had >50% of mutant embryos with
increased gata1comparedwithnegativecontrols, butthelevel
ofgata1expressionwasmixed,withsomeembryosdisplaying
a high level of gata1 expression and others less. Finally, level 1
compounds had <50% of mutant embryos with increased
gata1 and a generally weakly increased degree of gata1 ex-
pression when compared with negative controls (Fig. 2).
Whole-mount in situ hybridization. Whole mount in situ
hybridizations were performed as previously described using
62 PAIK ET AL.antisense riboprobes labeled with digoxigenin and detected
with antidigoxigenin antibody conjugated to alkaline phos-
phatase.
22The following antisense riboprobeswere generated
as described: cdx4, hoxa9a, hoxb7a,
18 ﬂi1,
23 gata1,
17 krox-20,
24
myoD,
25 pu.1,
16 and scl.
26 The in situ protocol was performed
using the Biolane  HTI machine (Holle & Huttner AG).
Genotyping. Genomic DNA was isolated from ﬁn clips or
whole embryos as previously described.
27 cdx4 heterozygous
ﬁsh and homozygous mutant embryos were genotyped as
previously described.
18
Results
Chemical screen to identify cdx4 modiﬁer phenotype
A total of 2640 compounds from the known bioactive col-
lection of the ICCB were tested. This same panel of com-
pounds had been tested previously in our laboratory during a
screen to identify small molecules that alter runx1 and c-myb
expression during deﬁnitive hematopoiesis.
5,10 Each com-
pound was tested individually in a single well, because pre-
liminary experiments with pooled compounds yielded high
levels of toxicity (data not shown). When tested individually
in our assay, 42 compounds were noted to cause develop-
mental delay (1.6%), 24 were teratogenic (0.9%), and 72 were
toxic to embryos (2.7%), resulting in death of all or most
embryos in the well.
A total of 5 compounds were scored as level 3 hits, 16
compounds as level 2 hits, and 18 compounds as level 1 hits.
All the level 2 and level 3 compounds and most of the level 1
compounds were purchased and a range of concentrations
were retested in the gata1=cdx4 in situ hybridization assay.
Twoofthelevel3compounds,bergaptenandasarylaldehyde,
had reproducible rescue of gata1 expression in cdx4 mutants,
whereasnoneoftheresultswithlevel1or2compoundscould
be repeated convincingly.
A small percentage (0.9%) of chemicals tested had only
wild-type embryos in the well, and thus no cdx4 mutants to
score. On the unlikely possibility that the chemical exposure
had completely rescued the cdx4-mutant phenotype render-
ing the cdx4-mutant animal indistinguishable from the wild-
type, the embryos in these otherwise unscorable wells were
FIG. 1. Screen design. cdx4 heterozygous
adult ﬁsh were incrossed weekly to generate
embryos for the chemical screen. Chemicals
from the Institute of Chemistry and Cell
Biology library were transferred by robotics
from 384-well plates to 48-well plates. Each
plate contained negative (1% DMSO) and
positive (20mM DEAB) control wells. About
20 synchronized embryos at 50% epiboly
stage were placed manually into each well of
the 48-well plates. Once the embryos reached
the 10-somite stage, they were ﬁxed and
whole-mount in situ hybrization was per-
formed with both gata1 and cdx4 riboprobes.
Each well was examined and scored manu-
ally. A posterior view of representative em-
bryos is shown, with anterior to the left and
posterior to the right. cdx4-mutant embryos
were identiﬁed by lack of cdx4 expression. In
most wells, cdx4-mutant embryos had little or
no gata1 expression. The wells with increased
gata1 expression in the cdx4-mutant embryos
were scored as a ‘‘rescue.’’ DMSO, dimethyl
sulfoxide; DEAB, 4-diethylamino benzalde-
hyde; WT, wild type. Color images available
online at www.liebertonline.com=zeb.
FIG. 2. Scoring system for rescued embryos. The level of gata1 rescue was determined by the percentage of rescued mutant
embryos in each well and by the intensity of gata1 expression in these embryos in comparison to the negative and positive
control wells for each individual plate. DMSO vehicle was the negative control, and 20mM DEAB was the positive control.
Representative mutant embryos are shown after in situ hybridization for gata1 and cdx4 expression. Color images available
online at www.liebertonline.com=zeb.
A CHEMICAL GENETIC SCREEN IN THE CDX4-MUTANT ZEBRAFISH 63genotyped to conﬁrmthey were allwild type orheterozygous
for the mutant cdx4 allele. In all cases no homozygous mutant
embryos with a wild-type phenotype were identiﬁed. Each of
these compounds were then retested, and none had cdx4-
mutant embryos with increased gata1 expression on subse-
quent testing.
Bergapten rescues gata1 expression in cdx4-mutant
embryos but has minimal effect on the expression
of other posterior mesodermal genes
Bergaptenandasarylaldehydewerefoundtoincreasegata1
expression in cdx4-mutant embryos. We decided to focus on
bergapten only, because asarylaldehyde had a very simple
chemical structure, such that we could not identify related
compounds to study. Bergapten, also known as 5-MOP, is a
member of the psoralen family, which is found in bergamont
oil.
28 Psoralen family members have been utilized in the
treatment for psoriasis and cutaneous T-cell lymphoma, in
combination with ultraviolet A (UVA) phototherapy (re-
viewed in Ref.
29). The original concentration of bergapten in
the screening well was estimated to have been approximately
30mM. When a serial dilution of purchased bergapten was
tested, maximal rescue of gata1 expression was observed at
33mM, whereas treatment with 100mM bergapten was toxic
(Fig. 3A). In one representative experiment, 36% of the em-
bryos treated with 100mM bergapten were dead by the 10-
somite stage (24=67), and 51% of the live embryos were dys-
morphic (22=43).
To determine whether bergapten also affected other pos-
terior tissues in the developing embryo, we examined the
expression patterns of multiple mesodermal genes, including
ﬂi1, scl, and pu.1,i ncdx4-mutant embryos treated with ber-
gapten (Fig. 3B). In wild-type embryos, all of these genes are
expressed in the ALM and PLM from the three-somite
stage.
23,26 ﬂi1 marks vascular progenitors, whereas scl is ex-
pressed by both vascular and hematopoietic cells, and pu.1 is
expressed by committed myeloid cells.
15–16 The cdx4-mutant
embryos have decreased expression of ﬂi1 and scl in the PLM,
and almostnormalexpression intheALM.Whentreated with
either DEAB or bergapten, there was no observable difference
between the expression level of ﬂi1 or scl in untreated wild-
type embryos and embryos treated with DEAB or bergapten.
Although the overall expression domain in the posterior
mesoderm is shorter in the cdx4-mutant embryos treated with
DEAB or bergapten, the intensity of expression is unchanged
compared with untreated cdx4 mutants (Fig. 3B). In contrast,
the expression of pu.1 is absent in the PLM of cdx4 mutants
and appears relativelynormal in theALM. When treated with
bergapten, cdx4-mutant embryos have increased expression
of pu.1 in the PLM, similar to the rescue effect observed with
gata1 expression. This same result is also evident after incu-
bation with DEAB. This indicates that both DEAB and ber-
gapten may expand primitive blood development by acting
FIG. 3. Bergapten increases gata1 and pu.1 in
cdx4-mutant embryos. All embryos are dis-
played with anterior to the left and posterior to
the right. (A) cdx4 heterozygous adults were
incrossed, and the resulting embryos were trea-
ted with varying doses of bergapten. Bergapten
rescues gata1 expression (level 3) in the cdx4-
mutant embryos, and this rescue is most effec-
tive at 33mM. Whole-mount embryos at the
10-somite stage are displayed from a represen-
tative experiment. (B) cdx4 heterozygous adults
were incrossed, and the resulting embryos were
treated with DMSO vehicle control, 20mM
DEAB, or 30mM bergapten. Flatmounted em-
bryos at the 10-somite stage are shown. WT
embryos and cdx4 mutants stained with pu.1
were conﬁrmed by genotyping. Bergapten does
not change the expression pattern of mesoder-
mal genes ﬂi1, scl, and pu.1 in WT embryos. In
cdx4-mutant embryos, however, pu.1 expression
is rescued in the posterior lateral mesoderm
when either DEAB or bergapten is applied. Ber,
bergapten. Color images available online at www
.liebertonline.com=zeb.
64 PAIK ET AL.upon a common erythromyeloid progenitor, but these com-
pounds do not appear to act upon hemangioblasts.
Bergapten disrupts A-P patterning
The morphology of the gata1þ stripes in the posterior me-
soderm was similar in both DEAB-treated and bergapten-
treated embryos, but the anterior portion did not merge
toward the midline as seen in wild-type embryos at the 10-
somite stage. We hypothesized that bergapten and DEAB
would have similar effects on A-P patterning overall. Having
observed that posterior expression of gata1, pu.1, scl, and ﬂi1
had similar patterns for embryos treated with either DEAB or
bergapten, we examined anterior patterning more closely by
studying the expression of krox-20 and myoD.A skrox-20
stains rhombomeres 3 and 5 in the hindbrain, whereas myoD
stains the somites, this allowed a measurement of the distance
between the hindbrain and the most anterior somite pair.
Previous studies have shown this distance between krox-20
and myoD to be highly sensitive to RA concentration, as
demonstrated in mutants with disrupted RA signaling.
30
Likewise, treatment of wild-type embryos with DEAB is re-
ported to have a similar effect.
7 When treated with DEAB, the
gap between krox-20 and myoD expression disappears, indi-
cating defects in the posterior hindbrain. This result is iden-
tical for embryos treated with 33mM bergapten, whereas a
clear gap is noted in the untreated control embryos
(138.6 7.6mm) (Fig. 4B). These data indicate that bergapten
and DEAB have similar effects on A-P patterning. When the
same krox-20–myoD assay was conducted with embryos ob-
tainedfromanincrossofcdx4heterozygousanimals,embryos
were found to lose the gap between krox-20 and myoD re-
gardless of their genotype. However, in the cdx4-mutant
embryos, krox-20 expression overlapped with that of somite 1
and 2, indicating that A-P patterning in the cdx4-mutant
embryos was more severely affected compared with their
siblings (Supplemental Fig. S1, available online at www
.liebertonline.com). As DEAB is known to inhibit RA bio-
synthesis,
19,31 it is possible that bergapten mayalso inhibit the
RA pathway through an unknown mechanism.
8-MOP has similar effect as bergapten on gata1
expression, whereas PAP-1 does not
To determine if structurally similar psoralen compounds
relatedtobergaptenmayhavesimilareffectsonhematopoiesis,
8-MOP and PAP-1 were tested in these same assays. Like ber-
gapten,8-MOPisusedclinicallytotreatpsoriasisandhasDNA
intercalatingactivity(reviewedinRef.
29).Incontrast,PAP-1isa
potassium channel blocker, which is also used for clinical
treatment of psoriasis, but with decreased phototoxicity due to
bulky side groups attached to the psora ring
32 (Fig. 4A).
We ﬁrst tested if 8-MOP and PAP-1 also affect A-P pat-
terning in wild-type embryos using the krox-20–myoD assay
mentioned earlier. As expected, 8-MOP disrupts the posterior
hindbrain for all doses tested, with maximal effect at 33mM,
albeitat lesserdegree whencompared withbergapten-treated
embryos (average krox-20=myoD distance of 8-MOP-treated
embryos¼85.8 4mm) (Fig. 4B; data not shown). In contrast,
PAP-1 does not affect the distance between krox-20 and myoD
(average distance¼141.2 13mm). When we examined the
abilityof8-MOPandPAP-1torescuegata1expressionincdx4-
mutant embryos, 8-MOP increased gata1 expression at 33mM,
whereas PAP-1 did not (Fig. 4C). Overall, 8-MOP seems to act
FIG. 4. Bergapten and other psoralen compounds affect anterior–posterior patterning. (A) Chemical structures of the com-
pounds tested. (B) Whole-mount in situ hybridization of WT AB embryos with krox-20 and myoD riboprobes. Whole-mount 10-
somite stage embryos are shown from a representative experiment. The average distance between krox-20 and myoD in control
embryosis138.6mm( 7.6mm).Thebergapten-treatedembryoslosethegapbetweenkrox-20andmyoD,similartoDEAB-treated
embryos.8-MOPalsoaffectsthedistance,buttoalesserdegree(85.8 4mm).Incontrast,PAP-1doesnotaffectthisdistance.(C)
cdx4 heterozygous adults were incrossed, and the resulting embryos were treated with DMSO vehicle control, 20mM DEAB,
33mM 8-MOP, or 33mM PAP-1. Whole-mount in situ hybridization was done with gata1 and cdx4 riboprobes at the 10-somite
stage. 8-MOP robustly rescues gata1 expression in the cdx4-mutant embryos, whereas PAP-1 does not rescue. ss, somite stage;
PAP-1,5-(4-phenoxybutoxy)psoralen;8-MOP,8-methoxypsoralen.Colorimagesavailableonlineatwww.liebertonline.com=zeb.
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mesodermal lineage gene expressions, including scl, ﬂi1, and
pu.1, was identical to bergapten (Supplemental Fig. S2,
available online at www.liebertonline.com).
Discussion
In this study, we conducted a chemical modiﬁer screen in
the cdx4 mutant background to identify pathways that inter-
act with the cdx4 pathway in regulating primitive hemato-
poiesis. On screening a library of known bioactive
compounds, bergapten, a member of the psoralen family, was
found to increase gata1 expression in cdx4-mutant embryos.
Further investigation of additional psoralen family members,
including 8-MOP and PAP-1, revealed that 8-MOP acts sim-
ilarly to increase gata1, albeit less robustly than bergapten.
In addition to the gata1 rescue, these compounds also affected
A-P patterning, particularly of the hindbrain, as evidenced by
the decreased distance between krox-20 and myoD expression
pattern in embryos treated with psoralen family members.
This pattern was reminiscent of embryos treated with an in-
hibitor of RA biosynthesis, as well as genetic mutants with
disruption in RA signaling.
30,33
InhibitorsofRAsignaling,suchasDEAB,havebeenshown
previously to increase gata1 expression during primitive he-
matopoiesis in zebraﬁsh (J.L.O. de Jong and L.I. Zon, un-
published data). Taken together, these results suggest that the
mechanism of gata1 rescue by psoralen compounds may also
result from inhibitory effects on the RA pathway. No direct
interaction is known between psoralens and retinoids, al-
though both are used to treat diseases of the skin, such as
psoriasis. Case reports suggest that there may be an additive
or even synergistic effect when using both retinoids and
psoralens with UVA to treat scleroderma.
34 Another report
hasshownthatpsoralenswithUVAincreasetheexpressionof
CYP2S1, a cytochrome P450 enzyme that is predominant for
the metabolism of RA in the skin.
35 If an analogous mecha-
nism were present in our assay, then bergapten may induce
the expression of cyp26a1 or another metabolizing enzyme in
the developing zebraﬁsh, thereby decreasing the effective RA
concentration by enhanced biodegradation.
To test if bergapten disrupts RA signaling, an epistasis
experiment was conducted by simultaneously treating wild-
type embryos with both bergapten and RA. The expression
patternofkrox-20andmyoDwasthesameforembryostreated
with RA alone (data not shown), indicating that bergapten
does not suppress exogenous RA signaling, and suggesting
that if bergapten does affect the RA pathway, it most likely
functions upstream of raldh2, the rate-limiting enzyme for RA
biosynthesis.
33,36 It could also be possible that while bergap-
teninducescyp26a1,theRA-metabolizingenzyme,thelevelof
cyp26a1 may not be sufﬁcient to metabolize a high concen-
tration of exogenous RA. Additional experiments are needed
to determine whether the activity of the psoralens in blood
development is due to inhibition of RA biosynthesis, activa-
tion of RA metabolism, or a parallel pathway.
In addition to the RA pathway, we also examined if ber-
gapten rescues gata1 via the hox pathway. It has been previ-
ously reported that cdx4 homozygous mutant embryos lose
posterior hox gene expression, and that hoxb7a and hoxa9a
overexpression in these embryos rescue gata1 expression.
18
However, when examined by in situ hybridization, the levels
of hoxb7a and hoxa9a RNA expression in the control and
bergapten-treated embryos were identical (Supplemental
Fig. S3, available online at www.liebertonline.com). This in-
dicates that bergapten rescues gata1 expression via a mecha-
nism that is independent of the hox pathways.
Multiple steps need to be carefully considered before per-
forming a modiﬁer screen on a mutant background. First is
the variability in the rescue phenotype. During this screen,
signiﬁcant plate-to-plate variability of gata1 expression in the
untreated mutant embryos was noted. This was likely due to
slight differences in staging and nonsynchronized embryos.
Another inﬂuencing factor was the in situ hybridization step,
which depended on the quality of the riboprobe used and the
length of staining time. Of note, even with the most robust
rescues, increased gata1 expression was never observed
in 100% of the cdx4-mutant embryos in a given well. Using
50% as the threshold proved to be adequate to identify legit-
imate hits.
A second point to be considered is the toxicity of chemicals
totheembryos.Theoveralltoxicitydetectedinourscreenwas
5.2%. This was more than double the 2% toxicity level expe-
rienced by North et al. (T.E. North, pers. comm.), who
screened the same chemical library we did. Of note, in our
screen, embryos were incubated at an earlier stage than in the
screen by North et al., whose embryos were incubated from
the three-somite stage to 36h postfertilization.
5 Not surpris-
ingly, incubation during gastrulation resulted in a higher rate
of toxicity. This should be taken into account when designing
a chemical screen, along with the stages when the mutant
geneisanticipated tohavethemostinﬂuence.Forexample,as
cdx4 has important A-P patterning effects during gastrulation
that set upthe expression levelsof theposterior hox genes, our
screen was designed to include chemical exposure during
gastrulation. The effect of bergapten on gata1 is diminished
when added to embryos after completing gastrulation (data
not shown), and so if our screen had been designed for later
chemical exposure time, we may not have detected bergapten
as a hit.
Chemical modiﬁer screens using a mutant background can
provideusefulknowledgeabouttheaffectedpathwaysinthat
mutant,particularlyrelatedtoaspeciﬁcphenotypeofinterest.
We have shown in our study that the loss of gata1 and pu.1
expression in the cdx4-mutant embryos is rescued by chang-
ing A-P axis development. The zebraﬁsh community has
many mutants with hematopoietic defects that are affected at
various steps during hematopoietic development, including
mutants with defective hematopoietic stem cells and mutants
with problems at later stages of blood differentiation. Con-
ducting a chemical modiﬁer screen in these various mutants
will increase our understanding of normal hematopoietic
development and may provide insight into aberrant devel-
opment and hematopoietic malignancies.
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